Munich Reinsurance Co Stock Corp in Munich Purchases 52,494 Shares of Edwards Lifesciences Corporation $EW

Key Points

• Munich Reinsurance Co Stock Corp in Munich boosted its stake in Edwards Lifesciences by 3,673.5%, buying 52,494 shares to hold 53,923 shares valued at about $4.65 million.
• Edwards beat Q1 estimates and raised guidance — Q1 EPS of $0.78 (vs. $0.73 est.) and $1.65B revenue, with FY2026 EPS guidance lifted to $2.95–$3.05 and a $500M accelerated share‑repurchase announced.
• Notable insider selling — executives have sold 86,058 shares (~$7.12M) in the last 90 days, a potential near‑term concern despite ~79.5% institutional ownership.

Munich Reinsurance Co Stock Corp in Munich increased its position in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 3,673.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 53,923 shares of the medical research company's stock after acquiring an additional 52,494 shares during the quarter. Munich Reinsurance Co Stock Corp in Munich's holdings in Edwards Lifesciences were worth $4,648,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. raised its holdings in Edwards Lifesciences by 0.5% in the 3rd quarter. Vanguard Group Inc. now owns 70,363,210 shares of the medical research company's stock worth $5,472,147,000 after acquiring an additional 365,581 shares during the period. Wellington Management Group LLP increased its holdings in shares of Edwards Lifesciences by 4.9% during the 3rd quarter. Wellington Management Group LLP now owns 20,804,416 shares of the medical research company's stock worth $1,617,959,000 after purchasing an additional 977,933 shares during the period. Bank of New York Mellon Corp raised its position in shares of Edwards Lifesciences by 8.1% during the third quarter. Bank of New York Mellon Corp now owns 19,010,227 shares of the medical research company's stock valued at $1,478,425,000 after buying an additional 1,423,365 shares during the last quarter. Jennison Associates LLC lifted its stake in shares of Edwards Lifesciences by 19.6% in the third quarter. Jennison Associates LLC now owns 13,958,774 shares of the medical research company's stock valued at $1,085,574,000 after buying an additional 2,287,783 shares during the period. Finally, Ninety One UK Ltd lifted its stake in shares of Edwards Lifesciences by 14.0% in the third quarter. Ninety One UK Ltd now owns 7,908,572 shares of the medical research company's stock valued at $615,050,000 after buying an additional 969,030 shares during the period. Institutional investors own 79.46% of the company's stock.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 24,000 shares of the business's stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $83.84, for a total value of $2,012,160.00. Following the transaction, the vice president directly owned 21,266 shares in the company, valued at $1,782,941.44. The trade was a 53.02% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Scott B. Ullem sold 13,000 shares of the business's stock in a transaction dated Thursday, April 9th. The shares were sold at an average price of $80.04, for a total transaction of $1,040,520.00. Following the completion of the transaction, the chief financial officer owned 39,699 shares in the company, valued at approximately $3,177,507.96. This trade represents a 24.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 86,058 shares of company stock worth $7,118,636 over the last ninety days. Corporate insiders own 0.31% of the company's stock.

Analyst Upgrades and Downgrades

EW has been the subject of several research reports. Robert W. Baird increased their target price on shares of Edwards Lifesciences from $85.00 to $87.00 and gave the company a "neutral" rating in a research note on Friday. Stifel Nicolaus set a $110.00 target price on shares of Edwards Lifesciences and gave the company a "buy" rating in a research note on Tuesday, January 20th. Piper Sandler reiterated an "overweight" rating and issued a $100.00 target price (up from $98.00) on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. Barclays reiterated an "overweight" rating and issued a $104.00 target price (up from $103.00) on shares of Edwards Lifesciences in a research note on Monday, January 12th. Finally, Wolfe Research upgraded shares of Edwards Lifesciences from a "peer perform" rating to an "outperform" rating and set a $92.00 target price for the company in a research note on Wednesday, April 1st. Three research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $95.39.

Edwards Lifesciences Price Performance

Shares of Edwards Lifesciences stock opened at $84.20 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.09 and a current ratio of 3.72. The firm's 50-day simple moving average is $81.71 and its 200-day simple moving average is $82.21. Edwards Lifesciences Corporation has a twelve month low of $72.30 and a twelve month high of $87.89. The firm has a market cap of $48.55 billion, a P/E ratio of 46.01, a price-to-earnings-growth ratio of 2.08 and a beta of 0.95.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.73 by $0.05. Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The business had revenue of $1.65 billion for the quarter, compared to analyst estimates of $1.60 billion. During the same period in the previous year, the business earned $0.64 EPS. The firm's revenue was up 16.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, research analysts expect that Edwards Lifesciences Corporation will post 2.96 EPS for the current fiscal year.

Edwards Lifesciences News Summary

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: Q1 beat and raised FY26 outlook — Edwards reported adjusted EPS above consensus and roughly matched/beat revenue, then raised its FY26 EPS and sales guidance (EPS range $2.95–$3.05; sales growth guidance raised). This is the primary driver behind the stock rally. EW's Q1 Earnings Beat, Revenues Match, '26 View Up, Stock Climbs
• Positive Sentiment: Strong structural‑heart momentum and margin expansion — Management highlighted accelerating TAVR and TMTT growth, margin improvement and product momentum (including recent approvals), which supports higher longer‑term profitability expectations. Edwards Lifesciences beats quarterly estimates on robust demand for artificial heart valves
• Positive Sentiment: Capital return and buyback activity — Company disclosed a $500M accelerated share‑repurchase during the quarter, which supports EPS leverage and likely contributed to positive investor reaction. Edwards Lifesciences jumps 5.2% as Q1 results top expectations and full-year guidance rises
• Positive Sentiment: Analyst support — Some firms raised price targets/ratings (BTIG raised its target and reiterated buy), reinforcing bullish sentiment after the print. Price target / analyst notes
• Neutral Sentiment: Q2 guidance roughly in line — Q2 EPS guidance of $0.70–$0.76 sits around consensus, so the print is more notable for the FY lift than an outsized Q2 beat. Q1 earnings call highlights
• Neutral Sentiment: Mixed metric reporting from third parties — Some outlets show differing adjusted vs. GAAP EPS or alternate line‑item figures; these reconcileable reporting differences may cause short‑term noise. Q1 financial snapshot (third‑party)
• Negative Sentiment: Substantial insider selling — Public filings and aggregators show multiple insider sales (many executives selling shares) over recent months, which some investors interpret as a negative signal on near‑term insider conviction. Insider trading summary
• Negative Sentiment: Cost pressures — Cost of sales rose noticeably year‑over‑year (reported by some summaries), which could limit margin upside if the trend continues despite current operating margin gains. Cost / margin details

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.